Figure 2. In-vitro binding assay of mutant [¹⁸F]FB-IL2v to PHA-activated and non-activated human PBMCs.

For blocking studies, cells were pre-incubated with 2 ng/ml of either wild-type IL2 or mutant IL2v, 30 min before tracer incubation at 4^°C. All the experiments were performed in triplicate. Error bars represent the standard deviation. Statistically significant differences between non-activated and activated cells are indicated by ^$$$(p < 0.001). Significant differences between untreated activated PBMCs and activated PBMCs pretreated with wild-type IL2 or mutant IL2v are indicated by ^* (p < 0.05), ^** (p < 0.01).